FRIENDSWOOD, Texas – (Business Line) – Castle Biosciences, Inc. (Nasdaq: CSTL), a company that promotes health through innovative testing that guides patient care, announced today that the company’s medical director, Matthew Goldberg, MD, FAAD, is a neuroscientist. Certified dermatologists and dermatologists will present at the Precision Medicine World Conference (PMWC®) 2023, January 25-27 in Santa Clara, California.
Dr. Goldberg’s presentation “Using Molecular Diagnosis to Inform Cancer Management Decisions” will take place on Wednesday, January 25 at 2:30 pm Pacific time as part of the track. 3: Molecular diagnosis and analysis in the clinic. Dr. Goldberg will highlight a range of tests in Castle’s melanoma and gastrointestinal tract, including DecisionDx®-Melanoma, DecisionDx®-SCC and TissueCypher® Barrett’s Esophagus test, and how personal information is provided. Can help doctors make more informed treatment decisions. In caring for their patients to enhance patient outcomes.
“Castle Biosciences is a leading medical company committed to changing Barrett’s disease management for skin and esophageal cancer,” says Dr. Goldberg. “Focusing on disease conditions with critical treatment needs that cannot be met, we use our innovative testing platform to provide meaningful improvements to risk-sharing approaches across our various disease states. Provides molecular testing.
“While there has been much discussion about the promise of personal medicine, Castle tests have the potential to improve patient outcomes and reduce the cost of the health care system. I look forward to sharing practical examples during my discussion of how molecular testing technology can be clinically accessible for the benefit of patient care today.
Dr. Goldberg has served as Castle’s medical director since 2020 and supports Castle’s commercial and pipeline testing. He graduated from the University of Princeton with summa cum laude and received his medical degree from Icahn Medical School in Mount Sinai. Dr. Goldberg completed his residency in dermatology at the University of California, San Francisco, and graduated with a degree in dermatology at the University of Southwest Texas.
Conference presentation content will be available to registered participants only. Please visit https://www.pmwcintl.com/ for more information and registration details.
About Precision Medicine World Conference
The PMWC, “Precision Medicine World Conference” is the largest and original annual conference dedicated to specific medicine. PMWC’s mission is to bring together leading leaders, top global researchers and medical professionals and innovators across healthcare and biotechnology to present practical content that helps bridge the knowledge gap between different fields, thereby promoting Fertilization and collaboration in efforts to accelerate. Development and spread of clear drugs.
Since 2009, PMWC has been recognized as an important foundation for all components of the healthcare and biotechnology community, providing a unique platform for exchanging information on the latest advances in technology in clinical research practice. And all aspects related to regulation and compensation.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostic company that improves health through innovative tests that guide patient care. The company aims to change disease management by keeping people first: patients, clinics, staff and investors.
Castle’s current portfolio includes tests for skin cancer, skin cancer, uveal melanoma, Barrett’s esophagus, and mental health conditions. In addition, the company has an active research and development program for testing for other diseases with high therapeutic requirements, including its own developmental tests to predict systemic responses in patients with moderate psoriasis. To severe atopic dermatitis and related conditions. To find out more, visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, Twitter And Instagram.
DecisionDx-Melanoma, DecisionDx-CMParrotDecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMParrotTissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.
A forward-looking statement
This press release contains forward-looking statements within the meaning of Section 27A of the Amended Securities Act of 1933 and Section 21E of the Amended Securities Exchange Act of 1934 which is the subject of “Ports”. Security “created by those. Section. These anticipated statements include, but are not limited to, statements related to: the potential of our tests and the personal information they provide to assist physicians in making decisions about available treatments. More information on their patient care to enhance patient outcomes, reduce costs to the health care system and be accessed at clinics for the benefit of current patient care. The words “may”, “potential” and similar expressions are intended to define forward-looking statements, although not all forward-looking statements contain these identifying words. We may not be able to achieve the plans, intentions or expectations outlined in our forward statements, and you should not place undue reliance on our forward statements. Actual results or events can be very different from the intentional plans and expectations expressed in the forward-looking statements we make. These forward-looking statements relate to risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including without limitation: follow-up studies or test results; The findings may contradict previous studies or test results and findings, including those related to diagnostic tests and predictions discussed in this press release; The practical application of our tests may not provide the benefits described above to the patient. Insufficient insurance of or compensation for our tests from governments and commercial payers can limit our ability to reduce costs on the health care system. And the risks under the heading “Risk Factors” in our quarterly report on Form 10-Q for the three-month period ended September 30, 2022, and in our other documents with SEC. The anticipation statement can only be applied to the date it was made, and we have no obligation to update any forward-looking statements, except as required by law.